Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-AGT01 RVR in Mild to Moderate Hypertension Pretreated With Zilebesiran
NCT07553442Phase 2Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of zilebesiran in hypertension (HTN), sponsored by Alnylam Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07553442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553442.